A biotech firm aiming to fundamentally reverse chronic age-related diseases, Rejuvenate Bio, has secured $6.0M in Series A funding. The company is developing therapies that target the core drivers of conditions like heart disease, metabolic disease, and kidney failure in humans.
Rejuvenate Bio's mission centers on unlocking the power of gene expression and epigenetic reprogramming. By leveraging these biological mechanisms, the firm seeks to tackle pre-existing ailments and potentially alter the course of aging-related health decline.
.png&w=3840&q=75)
